Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function
- PMID: 2864051
- PMCID: PMC1400687
- DOI: 10.1111/j.1365-2125.1985.tb05037.x
Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function
Abstract
Chronic administration of nadolol has been reported to reduce blood pressure either without or with a concomitant fall of renal blood flow. We therefore studied the effects of nadolol 80 mg once daily on ambulatory blood pressure, renal and systemic haemodynamics in patients with mild to moderate essential hypertension. Ten patients took part in this randomized, double-blind, placebo-controlled, crossover study, each phase of which lasted 4 weeks. Nadolol significantly reduced ambulatory blood pressure and heart rate, but had no effect on blood pressure variability. Cardiac output was significantly reduced by nadolol and total peripheral resistance increased but without reaching statistical significance. Despite the fall in blood pressure and cardiac output, renal blood flow and glomerular filtration rate remained unchanged. The fraction of cardiac output reaching the kidneys rose significantly and renal vascular resistance was significantly reduced. Body weight, urinary sodium excretion and urine flow rate remained unchanged. We conclude that nadolol 80 mg once daily lowers ambulatory blood pressure in patients with mild to moderate hypertension without impairment of renal blood flow, indicating a redistribution of cardiac output to the kidneys. The mechanism of the renal vasodilator effect of nadolol remains to be determined.
Similar articles
-
Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study.Clin Sci (Lond). 1984 Aug;67(2):243-8. doi: 10.1042/cs0670243. Clin Sci (Lond). 1984. PMID: 6146425 Clinical Trial.
-
Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension.Am J Hypertens. 1988 Jul;1(3 Pt 3):263S-268S. doi: 10.1093/ajh/1.3.263s. Am J Hypertens. 1988. PMID: 3415803 Clinical Trial.
-
Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.J Clin Pharmacol. 1982 Apr;22(4):187-95. doi: 10.1002/j.1552-4604.1982.tb02161.x. J Clin Pharmacol. 1982. PMID: 6124557
-
Alterations in renal hemodynamics during chronic and acute beta-blockade in humans.Am J Hypertens. 1989 Nov;2(11 Pt 2):233S-236S. doi: 10.1093/ajh/2.11.233s. Am J Hypertens. 1989. PMID: 2573369 Review.
-
Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.Drugs. 1984;28 Suppl 2:35-50. doi: 10.2165/00003495-198400282-00004. Drugs. 1984. PMID: 6151890 Review.
Cited by
-
Noninvasive, automatic 24-h ambulatory blood pressure monitoring in normotensive subjects.Eur J Appl Physiol Occup Physiol. 1987;56(4):381-3. doi: 10.1007/BF00417763. Eur J Appl Physiol Occup Physiol. 1987. PMID: 3622479
-
Evaluation of Tc-99m-DTPA for renal clearance studies in the pig.Urol Res. 1988;16(6):449-54. doi: 10.1007/BF00280028. Urol Res. 1988. PMID: 3068880
-
Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.Eur J Clin Pharmacol. 1988;33(6):625-8. doi: 10.1007/BF00542499. Eur J Clin Pharmacol. 1988. PMID: 3366166
-
Effects of carvedilol on renal function.Eur J Clin Pharmacol. 1990;38 Suppl 2:S96-100. doi: 10.1007/BF01409473. Eur J Clin Pharmacol. 1990. PMID: 1974513 Clinical Trial.
-
Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension.Cochrane Database Syst Rev. 2014 Feb 28;2014(2):CD007452. doi: 10.1002/14651858.CD007452.pub2. Cochrane Database Syst Rev. 2014. PMID: 24585007 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical